Table IV.
Complications, adverse events, and mortality
| Complication | DS/BD (N = 173), % (n) | RYGB (N = 136), % (n) | P value |
|---|---|---|---|
| Gastrointestinal leak* | 1.7 (3) | 0 (0) | .26 |
| ED visit | 40.1 (69) | 25.0 (34) | <.01 |
| Readmission | 25.4 (44) | 23.5 (32) | .70 |
| Abdominal reoperation* | 29.2 (51) | 23.0 (32) | .25 |
| Cholecystectomy | 18 | 17 | |
| Ventral hernia repair | 22 | 6 | |
| Small bowel obstruction | 6 | 0 | |
| Panniculectomy | 7 | 4 | |
| Revision | 0 | 1 | |
| Other | 3 | 5 | |
| TPN/tube feeds | 7.6 (13) | 2.9 (4) | .08 |
| Infusion therapy† | 28.5 (49) | 23.5 (32) | .33 |
| Diagnostic/therapeutic upper endoscopy | 13.9 (24) | 22.1 (30) | .06 |
| Pancreatic enzyme supplementation‡ | 10.5 (18) | 0.74 (1) | <.001 |
| Hair loss | 67.1 (112) | 40.9 (54) | <.01 |
| Total events§ | 59.0 (105) | 49.3 (67) | .07 |
| Mortality* | 2.8 (5) | 2.2 (3) | 1 |
*
Rates based on 178 DS/BD patients and 139 RYGB patients.
†
Outpatient infusion of intravenous fluids due to dehydration.
‡
Pancrelipase (Creon [Abbot Laboratories, White Plain, NY] or Viokase [Aptalis, Birmingham, AL]).
§
Total number of patients experiencing any of the surveyed complications, excluding hair loss, enzyme supplementation, and mortality.
DS/BD, Duodenal switch/biliopancreatic diversion; ED, emergency department; RYGB, Roux-en-Y gastric bypass; TPN, total parenteral nutrition.